Hypertension, including isolated systolic hypertension, is one of the major risk factors for stroke and coronary heart disease in elderly subjects, and is a common antecedent of heart failure, because it increases the risk either directly through increased after-load or indirectly as a risk factor for acute myocardial infarction. The proportion of people aged 65 and above is increasing. It is well documented that hypertension treatment in elderly patients reduces cardiovascular morbidity and mortality more than could be expected from the results of trials in middle-aged subjects. Most of the trials on old and new antihypertensive drugs have yielded similar results. Nevertheless, evidence in subjects above 80 years of age is still limited. Hypertension (systolic-diastolic) and isolated systolic hypertension should be treated in elderly patients, starting with low doses of medication, particularly diuretics alone or in combination with betablockers or angiotensin-converting enzime inhibitors. Isolated systolic hypertension could also be treated with
Introduction
The proportion of people aged over 65 years is increasing. Comorbid conditions and physiological alteration in the elderly 1 should be considered before treatment in order to decide on pharmacotherapy. Hypertension is one of the major risk factors of stroke and heart disease and is also a common antecedent of congestive heart failure (CHF), renal failure, chronic occlusive peripheral vascular disease, and aortic aneurysm. 2 The prevalence of isolated systolic hypertension (ISH) defined as systolic blood pressure (SBP) у160 mm Hg and diastolic blood pressure (DBP) Ͻ90 mm Hg, rises curvilinearly with age, and it has been pathogenically linked with an age-related decrease in the elasticity of the large arteries. ISH is also considered a frequent antecedent of heart failure. [3] [4] [5] Clinical trials in hypertension (Table 1) HEP Study 6 This was a non-double-blind, randomised, controlled trial, carried out in 884 patients aged 60 to Correspondence: Dra. Maritza Orozco Valero. Centrol Clinico Profesional Caracas, piso 3 consultorio 300. Av. Panteó n con Alameda; San Bernardino. Caracas, Venezuela a long-acting calcium antagonist starting with low doses. The large therapeutic studies, because of the limitations imposed upon conclusions by the selection and exclusion criteria, by the statistical techniques that established the trial designs and by other study-related constraints, cannot be applied to all elderly patients seen in daily practice. Specifically patients may differ in age, severity of illness, presence of morbidity and a myriad of other clinical nuances. Non-pharmacological measures such as lifestyle modifications (losing weight, limiting alcohol intake, reducing sodium intake and exercise), should be instituted or improved if they existed, to maximise the benefit and minimise the risk inherent in pharmacological treatment. A medical approach may reconcile the results of these large therapeutic studies with 'real life' quality of life and patients' preferences in order to improve treatment compliance. 79 years. The antihypertensive agents were atenolol titrated from 50 to 100 mg, bendrofluazide 5 mg alone or in combination with atenolol 50 mg, or when 100 mg of atenolol was not tolerated. If atenolol-diuretic combination failed in decreasing BP, 500 mg of methyldopa was added at night time, if it was not effective, nifedipine SR 20 mg b.i.d. was indicated in addition. Average study duration was 4.4 years. The reduction in BP was 18 mm Hg SBP, 11 mm Hg DBP. In the treatment group, the rate of fatal and non-fatal stroke decreased 58%, the fatal stroke decreased 30% compared with the control group. Total mortality and myocardial infarction (MI) were unaffected by treatment. About a quarter of the patients were unable to tolerate beta-blocker (BB) because of side effects, ie general fatigue, muscular weakness, and breathlessness on exertion.
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A double-blind, randomised, placebo-controlled trial, which included 840 patients aged 60-70 years, who were randomised either to active treatment (hydrochlorothiazide (HCTZ) 25 mg plus triamterene 50 mg) or to a matching placebo. The active treatment could be increased to double, when BP remained high and after one more month methyl- dopa tablets titrated from 250 mg to 2 g (daily) could be added to the active treatment group, and placebo tablets to the placebo group. The mean follow-up was 4.7 years. The mean reduction on BP treatment groups was 20 mm Hg SBP/10 mm Hg DBP. Cardiac mortality was reduced by 38%, and cardiovascular (CV) mortality by 27%, compared with the placebo group. Non-significant decrease in cerebrovascular mortality was observed. Deaths from MI were significantly reduced by 60%. Others benefits identified were decreased in severe CHF and stroke. In this single-blind, randomised, placebo-controlled study, 1632 patients aged 60-79 years were recruited and alternatively allocated to either sustained-released (SR) nifedipine preparation or placebo after a 4-week placebo period, with a mean follow-up of 2.6 years. A titration of nifedipine dosage from 10 mg tablet twice a day to 60 mg once a
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Journal of Human Hypertension day was carried out. If the desired BP levels were not reached 20-50 mg/day captopril or 25 mg/day dihydrochlorothiazide (DHCTZ) or both, were given until the BP goal had been attained. BP reduction with SR nifedipine was 21.65 ± 17.96 mm Hg SBP and 13.14 ± 9.84 mm Hg DBP. In the placebo group BP decreased 12.31 ± 16.56 mm Hg SBP and 7.59 ± 10.08 mm Hg DBP. The active treatment reduced severe clinical outcomes and total CV mortality significantly, it also decreased combined CV events by 62%; major CV events such as strokes, reduction and severe arrhythmia attained significance when considered separately.
Clinical trials in ISH (SBP у160 DBP Ͻ95 mm Hg) ( Table 1) SHEP 12 A randomised, double-blind, placebo-controlled study, carried out in 4736 patients with ISH, mean age 60 years, mean duration 4.5 years, as active treatment were administered: (a) chlorthalidone from 12.5 mg to 25 mg or placebo, (b) atenolol 25-50 mg or placebo, (c) when BB was contraindicated reserpina 0.05 mg was given. The average SBP of the active treatment group was lower during the trial by about 26 mm Hg and about 11 mm Hg lower than the placebo group. The average DBP of the active treatment group was about 3 to 4 mm Hg lower than the placebo group. Active treatment diuretic decreased the incidence of total stroke by 36%, all cardiovascular events by 32%, death rate from all causes by 13%, compared with placebo treatment, as well as significantly decreasing the fatal or nonfatal heart failure and MI.
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Trial design was a randomised, double-blind, placebo-controlled study; 4695 patients with ISH, aged 60 to 100 years were randomly assigned to either a placebo group or to an active group. Active treatment consisted of nitrendipine 10-40 mg, enalapril 5-20 mg, HCTZ 12.5-25 mg or both. Mean followup was 2 years. SBP and DBP decreased 23 mm Hg/7 mm Hg in active treatment compared with placebo, the differences were SBP 10.1 mm Hg and DBP 4.5 mm Hg. In the active treatment group total stroke was reduced to 42%, non-fatal stroke decreased by 44%, fatal and non-fatal CV end points decreased by 31%, non-fatal cardiac end points decreased by 33%, and sudden death 26%, compared with the placebo group.
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This was a single-blind, placebo-controlled trial that recruited 1253 patients aged 60 years and over with a mean follow-up of 2 years. All patients were initially started on masked placebo. Alternate patients were assigned nitrendipine at 10-40 mg daily with the addition of captopril 12.5-50 mg daily or HCTZ 12.5-50 mg daily or both, if a BP fall was not obtained. Principal objectives were to investigate whether active treatment could reduce the incidence of stroke and other CV complications in older patients with ISH. After 2 years of follow-up, sitting systolic and diastolic BP in the active treatment group decreased 20 mm Hg SBP and 5 mm Hg DBP compared with placebo reduction which was 9.1 mm Hg and 3.2 mm Hg DBP. In the active treatment total stroke was reduced by 38% (from 20.8 to 13.0 end points per 1000 patients-years), all-causes of mortality by 39% (from 28.4 to 17.4 end points per 1000 patient-years), CV mortality 39% (from 15.2 to 9.4 end points per 1000 patient-years), stroke mortality by 58% (from 6.9 to 2.9 end points per 1000 patient-years) and all fatal and non-fatal CV end points by 37% (from 33.3 to 21.4 end points per 1000 patient-years).
Discussion and conclusions
The treatment trials of hypertension in the elderly shows the reduction of cardiovascular events by treating both hypertension and ISH. SHEP and SystEur trials found a reduction in cardiac mortality in the elderly that was greater than expected from the results of trials in middle-aged subjects. The benefit-risk comparison from active treatment needs to be determined in the very elderly (older than 80 years), the 'Hypertension in the Very Elderly Trial' (HYVET) in part will study this issue. 15 In older persons SBP is a better predictor of CV, cerebrovascular, renal and total mortality events than is DBP. 16 Looking at the results of ISH in the elderly, drug treatment is justified in older patients whose SBP is 160 mm Hg or higher, in this case, treatment prevents stroke more effectively than coronary events. In ISH patients, low doses of diuretics (12.5 mg of HCTZ or chlorthalidona) or long-acting formulations of calcium antagonists should be given.
The cardiovascular benefits of diuretics for elderly hypertensive patients is clear but not for those receiving beta-blockers. 17 Combinations containing low doses of diuretics, ie BB-diuretics, ACEIsdiuretics, are highly effective with less dosedependent adverse effects. 18, 19 Non-pharmacological measures such as lifestyle modifications should be instituted or improved if they existed to maximise the benefits and minimise the risk inherent in pharmacological treatment. 19, 20 Physiological changes such as: reduced myocardial contractility, renal function, total body water, baroreceptor responsiviness, and cognitive function, together with comorbidities (angina, atrial tachycardia or fibrilation, diabetes, essential tremor, heart failure, prostatism, renal insufficiency) in the elderly, must be taken into account in order to choose the adequate individual therapy. Medical approach may reconcile the result of large therapeutic studies with 'real life', quality of life and patients preferences.
